Robert Eisner
Distinguished in Large-Cell Immunoblastic Lymphoma

Dr. Robert Eisner

Hematology | Palliative Medicine | Oncology
Endeavor Health
Endeavor Health Medical Group
2650 Ridge Ave., Kellogg Cancer Center, 
Evanston, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Large-Cell Immunoblastic Lymphoma
Endeavor Health
Endeavor Health Medical Group
2650 Ridge Ave., Kellogg Cancer Center, 
Evanston, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Michael Eisner, DO, a hematologist at Endeavor Health, provides care for patients with blood cancers and related disorders. He treats conditions such as leukemia, lymphoma, anemia and clotting disorders. Dr. Eisner works closely with multidisciplinary teams to develop evidence-based care plans tailored to each patient’s diagnosis.

Dr. Eisner is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, and B-Cell Lymphoma.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Midwest University, 2000
Residency
Loyola University Medical Center Graduate Medical Education, Internal Medicine, 2004
Specialties
Hematology
Palliative Medicine
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine
Fellowships
Loyola University Medical Center Graduate Medical Education, Hematology/Oncology, 2007
Hospital Affiliations
Swedish Hospital
Northshore University Healthsystem - Evanston Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Endeavor Health Medical Group
2650 Ridge Ave., Kellogg Cancer Center, Evanston, IL 60201
Call: 847-570-2112
Other Locations
Endeavor Health Medical Group
757 Park Ave. West, Kellogg Cancer Center, Highland Park, IL 60035
Call: 847-480-3800
Endeavor Health Medical Group
2180 Pfingsten Rd., Kellogg Cancer Center, Glenview, IL 60026
Call: 847-503-1000
Endeavor Health Medical Group
5140 N. California Ave., Suite 600-GMP, Chicago, IL 60625
Call: 773-989-3803

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL
Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL
Enrollment Status: Suspended
Publish Date: August 15, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

3 Total Publications

Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy.
Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy.
Journal: Blood advances
Published: February 24, 2025
View All 3 Publications
Similar Doctors
Leo I. Gordon
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Leo I. Gordon
Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Leo I. Gordon
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (12.3 miles away)
866-587-4322
Experience:
53+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Gordon has been practicing medicine for over 53 years and is rated as an Elite provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Reem Karmali
Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Reem Karmali
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (12.3 miles away)
866-587-4322
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Reem Karmali is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Karmali has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. Her top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Jane N. Winter
Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Jane N. Winter
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (12.3 miles away)
866-587-4322
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Winter is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Winter has been practicing medicine for over 49 years and is rated as an Elite provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

VIEW MORE LARGE-CELL IMMUNOBLASTIC LYMPHOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eisner's expertise for a condition
ConditionClose
    • Distinguished
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Eisner is
      Distinguished
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Eisner is
      Distinguished
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • B-Cell Lymphoma
      Dr. Eisner is
      Distinguished
      . Learn about B-Cell Lymphoma.
      See more B-Cell Lymphoma experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Eisner is
      Distinguished
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    • Chronic Lymphocytic Leukemia (CLL)
      Dr. Eisner is
      Distinguished
      . Learn about Chronic Lymphocytic Leukemia (CLL).
      See more Chronic Lymphocytic Leukemia (CLL) experts
    • Diffuse Large B-Cell Lymphoma (DLBCL)
      Dr. Eisner is
      Distinguished
      . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
      See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
    View All 16 Distinguished Conditions
    • Advanced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Eisner is
      Advanced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Adult Immune Thrombocytopenia
      Dr. Eisner is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Eisner is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Antiphospholipid Syndrome
      Dr. Eisner is
      Advanced
      . Learn about Antiphospholipid Syndrome.
      See more Antiphospholipid Syndrome experts
    • Autoimmune Hemolytic Anemia
      Dr. Eisner is
      Advanced
      . Learn about Autoimmune Hemolytic Anemia.
      See more Autoimmune Hemolytic Anemia experts
    • Childhood Acute Myeloid Leukemia
      Dr. Eisner is
      Advanced
      . Learn about Childhood Acute Myeloid Leukemia.
      See more Childhood Acute Myeloid Leukemia experts
    View All 20 Advanced Conditions
    • Experienced
    • Acute Eosinophilic Pneumonia
      Dr. Eisner is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Eisner is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Eisner is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Aleukemic Leukemia Cutis (ALC)
      Dr. Eisner is
      Experienced
      . Learn about Aleukemic Leukemia Cutis (ALC).
      See more Aleukemic Leukemia Cutis (ALC) experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Eisner is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anemia
      Dr. Eisner is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.